Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial
Purpose To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV). Design Prospective, comparative, randomized, interventional study. Methods Thirty-two eyes from 32 patients with myopic CNV were consecutively e...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2010-03, Vol.149 (3), p.458-464.e1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 464.e1 |
|---|---|
| container_issue | 3 |
| container_start_page | 458 |
| container_title | American journal of ophthalmology |
| container_volume | 149 |
| creator | Gharbiya, Magda Giustolisi, Rosalia Allievi, Francesca Fantozzi, Nicoletta Mazzeo, Luigi Scavella, Vittorio Gabrieli, Corrado Balacco |
| description | Purpose To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV). Design Prospective, comparative, randomized, interventional study. Methods Thirty-two eyes from 32 patients with myopic CNV were consecutively enrolled and randomly treated, in a 1:1 ratio, with intravitreal ranibizumab (0.5 mg) or bevacizumab (1.25 mg) as needed, after the first injection. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 6 months. Results No statistically significant difference in the BCVA improvement, as well as in the FCT reduction, was found between groups during follow-up ( P value at 1, 3, 6 months > .05). Complete resolution of fluorescein leakage was observed in all 16 bevacizumab-treated eyes and in 15 out of 16 (93.7%) ranibizumab-treated eyes. No ocular or systemic adverse effects from treatment were encountered. Conclusion This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs. |
| doi_str_mv | 10.1016/j.ajo.2009.10.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733696198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002939409007922</els_id><sourcerecordid>2747372271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-1422f64ad74a39b94d538a65aa93107b441ff31574fcd7b27aa290aa66fe72113</originalsourceid><addsrcrecordid>eNp9ks2KFDEQx4Mo7uzqA3iRBhFPPeZrkomCsA6rLqwf6Oo1VKfTbtp0Z0y6B2YO4kP4hD6JaWZ0YQ-ekip-_6pK_oXQA4LnBBPxtJ1DG-YUY5XjOSb4FpqRpVQlWSpyG80wxrRUTPEjdJxSm0MhubyLjigmkmJJZ-jH6irE4GrwxTsbNpDM6CG6HQwu9IXriw8wXAUfvjpTvN2GtYNnxXk_RNi4Idqs-gi9q9xu7KAqvtiYxlS8tBsw-9Tvn79OJ6QOndvZuliFrA3e5-tldODvoTsN-GTvH84T9PnV2eXqTXnx_vX56vSiNAtGhpJwShvBoZYcmKoUrxdsCWIBoBjBsuKcNA0jC8kbU8uKSgCqMIAQjZWUEHaCnuzrrmP4Pto06M4lY72H3oYxacmYUIKoZSYf3SDbMMY-D6cJZoLlYlRkiuwpE0NK0TZ6HV0HcZshPXmjW5290ZM3Uyp7kzUPD5XHqrP1P8VfMzLw-ABkG8A3EXrj0jVHuZpmzNzzPWfzj22cjToZZ3tjaxetGXQd3H_HeHFDbbzrXW74zW5tun6tTlRj_WlaommHsMJYKkrZH32qwpI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1036311326</pqid></control><display><type>article</type><title>Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gharbiya, Magda ; Giustolisi, Rosalia ; Allievi, Francesca ; Fantozzi, Nicoletta ; Mazzeo, Luigi ; Scavella, Vittorio ; Gabrieli, Corrado Balacco</creator><creatorcontrib>Gharbiya, Magda ; Giustolisi, Rosalia ; Allievi, Francesca ; Fantozzi, Nicoletta ; Mazzeo, Luigi ; Scavella, Vittorio ; Gabrieli, Corrado Balacco</creatorcontrib><description>Purpose To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV). Design Prospective, comparative, randomized, interventional study. Methods Thirty-two eyes from 32 patients with myopic CNV were consecutively enrolled and randomly treated, in a 1:1 ratio, with intravitreal ranibizumab (0.5 mg) or bevacizumab (1.25 mg) as needed, after the first injection. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 6 months. Results No statistically significant difference in the BCVA improvement, as well as in the FCT reduction, was found between groups during follow-up ( P value at 1, 3, 6 months > .05). Complete resolution of fluorescein leakage was observed in all 16 bevacizumab-treated eyes and in 15 out of 16 (93.7%) ranibizumab-treated eyes. No ocular or systemic adverse effects from treatment were encountered. Conclusion This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2009.10.010</identifier><identifier>PMID: 20172072</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Biological and medical sciences ; Cardiovascular disease ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - etiology ; Diabetic retinopathy ; FDA approval ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Fovea Centralis - drug effects ; Heart attacks ; Humans ; Injections ; Macular degeneration ; Male ; Medical imaging ; Medical sciences ; Middle Aged ; Miscellaneous ; Myopia, Degenerative - complications ; Ophthalmology ; Photodynamic therapy ; Pilot Projects ; Prospective Studies ; Ranibizumab ; Studies ; Tomography ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vision disorders ; Visual Acuity - drug effects ; Vitreous Body</subject><ispartof>American journal of ophthalmology, 2010-03, Vol.149 (3), p.458-464.e1</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>(c) 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-1422f64ad74a39b94d538a65aa93107b441ff31574fcd7b27aa290aa66fe72113</citedby><cites>FETCH-LOGICAL-c531t-1422f64ad74a39b94d538a65aa93107b441ff31574fcd7b27aa290aa66fe72113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002939409007922$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22499619$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20172072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gharbiya, Magda</creatorcontrib><creatorcontrib>Giustolisi, Rosalia</creatorcontrib><creatorcontrib>Allievi, Francesca</creatorcontrib><creatorcontrib>Fantozzi, Nicoletta</creatorcontrib><creatorcontrib>Mazzeo, Luigi</creatorcontrib><creatorcontrib>Scavella, Vittorio</creatorcontrib><creatorcontrib>Gabrieli, Corrado Balacco</creatorcontrib><title>Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Purpose To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV). Design Prospective, comparative, randomized, interventional study. Methods Thirty-two eyes from 32 patients with myopic CNV were consecutively enrolled and randomly treated, in a 1:1 ratio, with intravitreal ranibizumab (0.5 mg) or bevacizumab (1.25 mg) as needed, after the first injection. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 6 months. Results No statistically significant difference in the BCVA improvement, as well as in the FCT reduction, was found between groups during follow-up ( P value at 1, 3, 6 months > .05). Complete resolution of fluorescein leakage was observed in all 16 bevacizumab-treated eyes and in 15 out of 16 (93.7%) ranibizumab-treated eyes. No ocular or systemic adverse effects from treatment were encountered. Conclusion This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs.</description><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular disease</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - etiology</subject><subject>Diabetic retinopathy</subject><subject>FDA approval</subject><subject>Female</subject><subject>Fluorescein Angiography</subject><subject>Follow-Up Studies</subject><subject>Fovea Centralis - drug effects</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Injections</subject><subject>Macular degeneration</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Myopia, Degenerative - complications</subject><subject>Ophthalmology</subject><subject>Photodynamic therapy</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Ranibizumab</subject><subject>Studies</subject><subject>Tomography</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vision disorders</subject><subject>Visual Acuity - drug effects</subject><subject>Vitreous Body</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks2KFDEQx4Mo7uzqA3iRBhFPPeZrkomCsA6rLqwf6Oo1VKfTbtp0Z0y6B2YO4kP4hD6JaWZ0YQ-ekip-_6pK_oXQA4LnBBPxtJ1DG-YUY5XjOSb4FpqRpVQlWSpyG80wxrRUTPEjdJxSm0MhubyLjigmkmJJZ-jH6irE4GrwxTsbNpDM6CG6HQwu9IXriw8wXAUfvjpTvN2GtYNnxXk_RNi4Idqs-gi9q9xu7KAqvtiYxlS8tBsw-9Tvn79OJ6QOndvZuliFrA3e5-tldODvoTsN-GTvH84T9PnV2eXqTXnx_vX56vSiNAtGhpJwShvBoZYcmKoUrxdsCWIBoBjBsuKcNA0jC8kbU8uKSgCqMIAQjZWUEHaCnuzrrmP4Pto06M4lY72H3oYxacmYUIKoZSYf3SDbMMY-D6cJZoLlYlRkiuwpE0NK0TZ6HV0HcZshPXmjW5290ZM3Uyp7kzUPD5XHqrP1P8VfMzLw-ABkG8A3EXrj0jVHuZpmzNzzPWfzj22cjToZZ3tjaxetGXQd3H_HeHFDbbzrXW74zW5tun6tTlRj_WlaommHsMJYKkrZH32qwpI</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Gharbiya, Magda</creator><creator>Giustolisi, Rosalia</creator><creator>Allievi, Francesca</creator><creator>Fantozzi, Nicoletta</creator><creator>Mazzeo, Luigi</creator><creator>Scavella, Vittorio</creator><creator>Gabrieli, Corrado Balacco</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial</title><author>Gharbiya, Magda ; Giustolisi, Rosalia ; Allievi, Francesca ; Fantozzi, Nicoletta ; Mazzeo, Luigi ; Scavella, Vittorio ; Gabrieli, Corrado Balacco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-1422f64ad74a39b94d538a65aa93107b441ff31574fcd7b27aa290aa66fe72113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular disease</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - etiology</topic><topic>Diabetic retinopathy</topic><topic>FDA approval</topic><topic>Female</topic><topic>Fluorescein Angiography</topic><topic>Follow-Up Studies</topic><topic>Fovea Centralis - drug effects</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Injections</topic><topic>Macular degeneration</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Myopia, Degenerative - complications</topic><topic>Ophthalmology</topic><topic>Photodynamic therapy</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Ranibizumab</topic><topic>Studies</topic><topic>Tomography</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vision disorders</topic><topic>Visual Acuity - drug effects</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gharbiya, Magda</creatorcontrib><creatorcontrib>Giustolisi, Rosalia</creatorcontrib><creatorcontrib>Allievi, Francesca</creatorcontrib><creatorcontrib>Fantozzi, Nicoletta</creatorcontrib><creatorcontrib>Mazzeo, Luigi</creatorcontrib><creatorcontrib>Scavella, Vittorio</creatorcontrib><creatorcontrib>Gabrieli, Corrado Balacco</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gharbiya, Magda</au><au>Giustolisi, Rosalia</au><au>Allievi, Francesca</au><au>Fantozzi, Nicoletta</au><au>Mazzeo, Luigi</au><au>Scavella, Vittorio</au><au>Gabrieli, Corrado Balacco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>149</volume><issue>3</issue><spage>458</spage><epage>464.e1</epage><pages>458-464.e1</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>Purpose To compare the short-term efficacy and safety of intravitreal ranibizumab versus bevacizumab in treating myopic choroidal neovascularization (CNV). Design Prospective, comparative, randomized, interventional study. Methods Thirty-two eyes from 32 patients with myopic CNV were consecutively enrolled and randomly treated, in a 1:1 ratio, with intravitreal ranibizumab (0.5 mg) or bevacizumab (1.25 mg) as needed, after the first injection. ETDRS best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 6 months. Results No statistically significant difference in the BCVA improvement, as well as in the FCT reduction, was found between groups during follow-up ( P value at 1, 3, 6 months > .05). Complete resolution of fluorescein leakage was observed in all 16 bevacizumab-treated eyes and in 15 out of 16 (93.7%) ranibizumab-treated eyes. No ocular or systemic adverse effects from treatment were encountered. Conclusion This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20172072</pmid><doi>10.1016/j.ajo.2009.10.010</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2010-03, Vol.149 (3), p.458-464.e1 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733696198 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Cardiovascular disease Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Diabetic retinopathy FDA approval Female Fluorescein Angiography Follow-Up Studies Fovea Centralis - drug effects Heart attacks Humans Injections Macular degeneration Male Medical imaging Medical sciences Middle Aged Miscellaneous Myopia, Degenerative - complications Ophthalmology Photodynamic therapy Pilot Projects Prospective Studies Ranibizumab Studies Tomography Tomography, Optical Coherence Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision disorders Visual Acuity - drug effects Vitreous Body |
| title | Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T03%3A42%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choroidal%20Neovascularization%20in%20Pathologic%20Myopia:%20Intravitreal%20Ranibizumab%20Versus%20Bevacizumab%E2%80%94A%20Randomized%20Controlled%20Trial&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Gharbiya,%20Magda&rft.date=2010-03-01&rft.volume=149&rft.issue=3&rft.spage=458&rft.epage=464.e1&rft.pages=458-464.e1&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2009.10.010&rft_dat=%3Cproquest_cross%3E2747372271%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1036311326&rft_id=info:pmid/20172072&rft_els_id=1_s2_0_S0002939409007922&rfr_iscdi=true |